1. Biomarkers of Renal Tumors: the Current State and Clinical Perspectives;Golovastova MO;CURR UROL REP,2017
2. Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects;Huaqi Y;MOL CANCER THER,2019
3. Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, Zhang W. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers (Basel) 2021, 13(22).
4. Ballesteros PA, Chamorro J, Roman-Gil MS, Pozas J, Gomez DSV, Granados AR, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021, 13(23).
5. Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D et al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Cancers (Basel)2020, 12(2).